All patients
|
Unadjusted
|
1.42 (1.13–1.77)
|
0.002
|
1.45 (1.14–1.86)
|
0.003
|
Unadjusted HR, in localised disease only
|
1.47 (1.11–1.96)
|
0.007
|
1.52 (1.11–2.07)
|
0.009
|
Adjusted for risk group and trial treatment
|
1.43 (1.14–1.79)
|
0.002
|
1.49 (1.17–1.91)
|
0.001
|
Adjusted for each of the following factors separatelya
|
Age
|
1.45 (1.15–1.81)
|
0.001
|
1.47 (1.15–1.88)
|
0.002
|
Metastatic disease
|
1.38 (1.10–1.73)
|
0.005
|
1.42 (1.11–1.81)
|
0.005
|
Primary site
|
1.48 (1.18–1.86)
|
<0.001
|
1.52 (1.19–1.95)
|
0.001
|
Histology
|
1.41 (1.12–1.77)
|
0.004
|
1.44 (1.12–1.85)
|
0.004
|
Local treatment modalityb
|
1.45 (1.12–1.89)
|
0.006
|
1.30 (0.98–1.72)
|
0.07
|
Adjusted for age, metastatic disease, primary site, histology and local treatmenta
|
1.44 (1.10–1.89)
|
0.009
|
1.30 (0.97–1.74)
|
0.08
|
Adjusted HR, in localised disease only
|
1.48 (1.05–2.09)
|
0.026
|
1.29 (0.88–1.89)
|
0.19
|
Only patients who had local therapy; excluding progressive disease (n = 25) and where it was not known whether local therapy was given or not n = 22)
|
Unadjusted
|
1.22 (0.96–1.55)
|
0.11
|
1.28 (0.99–1.67)
|
0.06
|
Adjusted for type of local treatmentc
|
1.14 (0.87–1.51)
|
0.34
|
1.25 (0.92–1.68)
|
0.15
|
Adjusted for time between the start of chemotherapy and starting local treatment
|
1.12 (0.87–1.44)
|
0.37
|
1.18 (0.90–1.55)
|
0.22
|
Adjusted for age, metastatic disease, primary site, histology, local treatment, and time between the start of chemotherapy and starting local treatment
|
1.13 (0.84–1.50)
|
0.42
|
1.25 (0.91–1.71)
|
0.17
|